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Abstract
The immunoproteasome (iP) represents a specialized type of proteasomes, which plays an important role in the
clearance of oxidant-damaged proteins under inflammatory and pathological conditions determining the outcome
of various diseases. In Alzheimer’s disease (AD)-like APPPS1 mice Aβ-deposition is paralleled by iP upregulation,
most likely mediated through type I interferon induction. To define the impact of increased iP expression we
crossed APPPS1 mice with mice deficient in the iP subunit LMP7 resulting in impaired iP function. While LMP7
deficient APPPS1 mice showed no major change in cerebral Aβ-pathology, we observed an altered cytokine
response in microglia isolated from LMP7 deficient APPPS1 mice compared to LMP7 expressing APPPS1 control
mice. The altered microglial cytokine profile upon iP deficiency in the presence of extracellular Aβ-pathology was
associated with an improvement of Aβ-associated cognitive deficits typically present in APPPS1 mice. Our findings
suggest a role for iP in the regulation of the innate immune response towards extracellular Aβ-pathology and
indicate that inhibition of iP function can modulate the cognitive phenotype upon overexpression of Aβ.
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Significance statement
We herein show that the immunoproteasome (iP) signifi-
cantly modulates microglial pro-inflammatory cytokine
secretion in a murine model of AD and alters the
pathology-associated behavioral phenotype in these mice.
Since iP impairment did not affect Aβ plaque burden our
data demonstrate that inflammation has a critical effect
on cognitive outcome independent of Aβ-pathology. Our
study links iP function, the innate immune response and
cognitive performance for the first time in an in vivo
model of neurodegeneration and suggests that modulation
of the iP is a viable option for the treatment of AD.
Introduction
The ubiquitin-proteasome system (UPS) is a major regu-
lator of protein homeostasis, vital to regulatory processes
via degradation of short-lived proteins involved in the
cell cycle, differentiation, transcriptional regulation or
apoptosis, and is also important for the degradation of
misfolded and damaged proteins [22, 28]. Proteins des-
tined for degradation are labelled with a poly-ubiquitin
tag, which is recognized by the 19S regulatory cap of the
26S proteasome and broken down by the 20S core
containing the three catalytically active β1, β2 and β5
subunits. The immunoproteasome (iP) is an isoform,
which is constitutively expressed in immune cells and in-
duced by pro-inflammatory cytokines such as type I and
type II interferons (IFNs) in almost any other cell type.
IFN signaling leads to incorporation of the alternative
catalytically activite β subunits β1i/LMP2, β2i/MECL-1
and β5i/LMP7 into newly formed iPs [1, 28]. There are
subtypes of iPs which contain only one or two βi subunits
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[54], however the β5i/LMP7 subunit is indispensable
for iP formation [40]. Depending on the tissue and spe-
cific cells types, different proteasome compositions are
expressed and can coexist [7]. Previous studies have
demonstrated that iPs possess enhanced overall activity
compared to standard proteasomes [49] and extended
the role of iPs; under conditions of cellular stress and
inflammation, the inducible forms of proteasomes were
shown to be vital for the degradation of misfolded and
oxidant-damaged proteins to prevent disease progression
[40, 49]. Moreover, patients harboring mutations in prote-
asome subunit genes that cause proteasome associated
autoinflammatory syndromes (PRAAS) with proteasome
dysfunction combined with concomitant proteotoxic
stress, exhibit increased type I IFN production [7, 8].
Notably, the UPS also appears to be implicated in the
pathogenesis of neurodegenerative diseases [3, 12, 15]
such as Alzheimer’s disease (AD), the most common
neurodegenerative disorder [44]. Previous work has
shown that ubiquitinylated protein deposits accumulate
in the brains and cerebrospinal fluid of AD patients
[19, 24, 34, 38, 42, 56, 58] and in rodent models of
disease [33]. A malfunction of the UPS was reported in
AD patients [27] and mouse models involving extracel-
lular beta-amyloid (Aβ) deposits [41, 48]. However, it is
still unclear whether the presence of Aβ leads to proteaso-
mal impairment or if disrupted proteasome activity
enhances cellular toxicity. Besides intense investigations
on the function of the standard proteasome, recent publi-
cations demonstrate an upregulation of the iP in microglia
and astrocytes surrounding Aβ plaques in a mouse model
of AD, as well as positive correlation of iP activity with
increasing severity of tau pathology in AD patients [2, 41].
However, the precise role of iPs in regulating the innate
immune response towards Aβ deposits and a potential
impact of a modulation of iP activation on disease course
and cognitive function has not been explored in vivo so far.
To pinpoint the involvement of the iP in Aβ-pathology,
we analyzed the expression of iP subunits during the
course of normal aging and in AD-like pathology in
APPPS1 mice [45]. To further dissect the role of iPs in
AD-like pathology, we crossed APPPS1 mice to β5i/LMP7
deficient mice lacking exons 1–5 of the proteasome
subunit beta type 8 (PSMB8) gene, which encodes for
the catalytic iP subunit β5i/LMP7 and is inevitable
for iP formation, resulting in a loss of iP assembly in
LMP7 deficient mice [18].
Here we show that iP expression is increased upon
aging and accelerated by the onset of Aβ-pathology.
While the lack of LMP7 had no impact on the develop-
ment and progression of Aβ burden in APPPS1 mice,
the pattern of cytokines secreted by microglia was sig-
nificantly altered, resulting in an ameloriation of cogni-
tive deficits typically found in APPPS1 mice. These data
suggest that iPs contribute to the regulation of Aβ-driven
innate immune responses and modulate cognitive deficits
associated with AD pathology.
Materials and methods
Animals and tissue collection
APPPS1 mice harboring the Swedish amyloid precursor
protein (APP) mutation KM670/671NL in conjunction
with the presenilin 1 mutation L166P [45] were crossed
to β5i/LMP7 deficient mice [18], lacking exons 1 to 5 of
proteasome (prosome, macropain) subunit beta type 8
(PSMB8) gene, that encodes for LMP7. All experiments
used littermate mice of both genders. Mice were group
housed under pathogen–free conditions on a 12 h light/
dark cycle, and food and water were provided to the
mice ad libitum. All animal experiments were performed
in accordance to the national animal protection guidelines
approved by the regional offices for health and social ser-
vices in Berlin (LaGeSo). Animals were euthanized and
transcardially perfused with 1× phosphate buffered saline
(PBS). Brains were carefully removed and fixed in 4%
paraformaldehyde (PFA) for 2 days followed by immersion
in 30% sucrose for at least 1 day for immunohistochemical
analysis or was snap-frozen in a 2-methylbutane (Merck)
bath placed in liquid nitrogen for subsequent processing.
Real time RT- PCR
For isolation of RNA, brain tissue was homogenized in
TRIzol® (Life Technologies) and centrifuged for 10 min
at 12,000 x g (4 °C). The supernatant was mixed with
chloroform, vigorously mixed and incubated for 3 min
at room temperature. Samples were centrifuged for
15 min at 12,000 x g (4 °C) and the supernatant carefully
removed, mixed with chilled isopropanol and incubated
for 10 min at room temperature before a further 30 min
centrifugation step at 12,000 x g (4 °C). The resulting
pellet was dissolved in ethanol, centrifuged for 10 min at
7500 x g (4 °C), and ethanol removed. This step repeated
and the dry pellet dissolved in ultrapure H2O. cDNA
synthesis was performed using the Transcriptor High
Fidelity cDNA Synthesis kit (Roche) according to the
manufacturer’s instructions.
Real time PCR using TaqMan gene expression assays
(Applied Biosystems) for Hprt, PSMB9 (encoding LMP2);
PSMB8 (encoding LMP7), Ifn-α, Ifn-β, Isg15 and Cxcl10
(IP-10) were performed using a Rotor-Gene RG-3000
(Corbett Research).
Proteasome activity assay
Brain tissue was homogenized in TSDG buffer (10 mM
Tris pH 7.0, 10 mM NaCl, 25 mM KCl, 1.1 mM MgCl2,
0.1 mM EDTA, 1 mM DTT, 2 mM ATP, 10% glycerin)
and underwent 5 cycles of freezing and defrosting using
liquid nitrogen. Samples were centrifuged for 60 min at
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13,000 x g (4 °C) und protein concentration determined
using the Pierce BCA Protein Assay Kit (Thermo Fischer)
according to the manufacturers protocol. Samples were
loaded onto a 96-well plate followed by the addition of the
substrate Suc-Leu-Leu-Val-Tyr-AMC (Bachem). Plates
were incubated at 37 °C for 90 min and fluorescence
recorded using a Synergy-HT (Bio Tek) plate reader. To
exclude non-proteasomal substrate degradation, samples
were incubated for 10 min with epoxomicin (1 μM; 37 °C)
before loading on the plate and values were substracted
from lysates incubated with DMSO control. A standard
sample of purified 26S standard proteasome was loaded
onto each plate, and measurements from samples were
thereafter corrected against this control.
Immunohistochemical staining
Frozen tissue was cut in 30 μm thick sections and stored
free floating in cryoprotectant solution (30% ethylenglycol,
20% glycerol, 50 mM sodium phosphate buffer, pH 7.4) at
4 °C until further use. For immunohistological staining,
sections were rinsed in 1× PBS, incubated in blocking
buffer (1× PBS containing 0,3% Triton X-100 and 10%
normal goat serum) for 1 h at RT and primary anti-
bodies for 4G8 (1:1000; Covance) and Iba-1 (1:500;
Wako Chemicals) were diluted in 1× PBS/ 0.3% triton
X-100/ 5% normal goat serum and incubated over night
at 4 °C. Sections were washed with 1× PBS to wash
off excessive primary antibodies, incubated with spe-
cies specific peroxidase-coupled secondary antibodies
(goat anti-mouse or goat anti-rabbit (1:300, Dianova))
diluted in 1× PBS/ 0.3% Triton X-100/ 5% normal
goat serum and incubated for 1 h on a shaker at RT
before developed with liquid diaminobezadine (DAB)
(Dako, K3647). Sections were counterstained with
matured hematoxylin followed by dehydration in an
ascending alcohol series before covered using Roti®-
Histokitt II mounting medium.
For Congo red staining, cerebral free floating sections
were mounted on glass slides. Sections were incubated
in stock solution I (0.5 M NaCl in 80% ethanol, 1%
NaOH) for 20 min and in stock solution II (8.6 mM
Congo red in stock solution I, 1% NaOH) for 45 min.
After rinsing twice in absolute ethanol, sections were
counterstained with mature hematoxylin and dehydrated
in ascending alcohol series, twice rinsed in 98% xylene
for 1 min, before mounting using Roti®-Histokitt II
mounting medium. Light microscopy and stereology
were performed using a Stereo Investigator system
(MicroBrightField) and DV-47d camera (MicroBrightField)
mounted on an Olympus BX53 microscope (Olympus,
Germany). Fluorescence imaging was performed using an
Olympus XM10 monochrome fluorescence CCD camera
(Olympus, Germany).
Stereological quantification
Quantitative analyses of Aβ plaque load and numbers in
cerebral cortical sections were performed using the
Stereo Investigator system including an Olympus micro-
scope BX53, the QImaging camera COLOR 12 BIT and
a stage controller MAC 6000. For analyses, the Stereo
Investigator 64-bit software (MBF Bioscience) was used.
Cortical Aβ plaque burden as assessed by 4G8 or Congo
red staining was quantified with the Area Fraction
Fractionator method of the Stereo Investigator software
as previously described [55]. Briefly, the area covered by
Aβ was quantified using the following settings: counting
frame size 90 × 90 μm, scan grid size 400 × 500 μm and
Cavallieri grid spacing 10 μm. Iba-1+ microglia area cov-
ered was assessed with cellSens software (Olympus) and
the cortical region of interest was automatically analyzed
according to manufacturer’s instructions.
Protein extraction
Frozen brain tissue was homogenized according to a
4-step extraction method as described in [25] with slight
modifications. In brief, hemispheres were homogenized
consecutively in Tris buffered saline (TBS buffer)
(20 mM Tris, 137 mM NaCl, pH = 7.6), followed by a
45 min centrifugation step at 100,000 x g (4 °C). The
supernatant was collected as the Tris soluble fraction
and the pellet was resuspended in Triton-X buffer (TBS
buffer containing 1% Triton X-100). This was followed
by further identical centrifugation and resuspension
procedure and this cycle was repeated with SDS buffer
(2% SDS in ddH2O) and formic acid (FA; 70% formic
acid in ddH2O). Immediately before use, protease inhibi-
tors (Roche, 1 tablet per 10 ml) and a phosphatase
inhibitor cocktail 3 (Sigma) were added to the first two
buffers. Brain extracts were incubated 30 min on ice
(except SDS and FA homogenates, which was incubated
at RT) after resupending before centrifugation. Protein
concentrations of each fraction were determined using
the Quantipro BCA Protein Assay Kit (Pierce) according
to the manufacturers protocol using the Tecan Infinite®
200 M photometer (Tecan).
Immunoblot and native PAGE analysis
Expression levels of endogenous mouse and transgenic
human APP and major C-terminal cleavage products of
APP (CTFα and CTF) and LMP7 iP subunits were
assessed by Western blot analysis according standard
protocols [55]. SDS fractions of brain homogenates
described above were analyzed using primary antibodies
against β5i/LMP7 (pc, K63, labstock generated against
peptides of LMP7 protein; 1:5000; Prof. Peter M. Kloetzel,
Institute of Biochemistry, Charité – Universitätsmedizin
Berlin, Charitéplatz 1, 10,117 Berlin, Germany), APPct
(Sigma, A8717); 1:1000) and GAPDH (Santa Cruz;
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1:2000). An HRP-conjugated anti-rabbit IgG antibody (GE
healthcare) was used as secondary antibody and immuno-
reactive bands were visualized using the Amersham ECL
immunoblotting detection system (GE healthcare). For
native PAGE analysis, tissue was homogenized in TSDG
buffer (10 mM Tris pH 7.0, 10 mM NaCl, 25 mM KCl,
1.1 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 2 mM ATP,
10% glycerin) and extracts loaded onto precast native
PAGE gels (3%–12%, Invitrogen).
Detection of Aβ1–40 and Aβ1–42 species and cytokines by
multiplex mesoscale assays MSD
Aβ1–40 and Aβ1–42 and cytokine concentrations in brain
extracts and cell culture supernatants were determined
with the MSD 96-Well MULTI-SPOT® Human (6E10)
Abeta Triplex Assay (Meso Scale Discovery) or the
V-PLEX™ Mouse Cytokine Assay according to manufac-
turer’s instructions and analyzed on a SECTOR Imager
6000 plate reader (Meso Scale Discovery).
Microglia cell isolation and stimulation
For cell isolation procedure, the whole brain was placed
in HBSS on ice and further processed with neuronal kit
dissociation according to manufactures instructions.
Isolation of CD11b+ cells from brain tissue was per-
formed using the Neural Tissue Dissociation Kit (P)
(Miltenyi Biotech) and the magnetic cell sorting (MACS)
technique using CD11b-labeled magnetic Microbeads
(Miltenyi Biotech) according to manufacturer’s instructions.
50.000 CD11b+ microglia were cultured overnight in a
96 well plate. Culture medium was removed and LPS
(1 μg/ml) diluted in serum-free culture medium was
added to stimulate the cells. Equivalent amount of PBS in
serum-free medium was used as stimulation negative con-
trol. Supernatant for baseline measurements were collected
prior to LPS stimulation. After 14 h, medium was col-
lected, snap frozen in liquid nitrogen and stored at −80 °C
for further cytokine analysis as described above.
Behavioral analysis
Cognition was assessed using the novel object recogni-
tion task (NOR) and the Barnes maze test at the age of
250 days. Experimenters were blinded during testing and
data acquisition. All tests were performed in the animals’
active phase in sound proof testing chambers with con-
trolled temperature and humidity at the Berlin Animal
Outcome Unit (NeuroCure Cluster of Excellence, Berlin,
Germany). Experiments were conducted in a sound-
attenuated testing chamber with the illumination set at
30–40 lx. Mice were allowed to acclimate to the testing
area for at least 30 min prior to testing. Each animal was
allowed to explore freely for 5 min and activity was
recorded with an overhead camera using an automated
system (Viewer III Version 3.0.1.205, Biobserve, St.
Augustin, Germany). Animals were returned to their
home cage at the end of the trial. Twenty-four hours
after habituation, the animals were exposed to the familiar
arena with two identical objects placed at an equal dis-
tance and allowed to explore for 5 min. On the 3rd day,
one of the familiar objects was exchanged for a different,
novel object and the mice were allowed to explore the
Open field in the presence of the familiar and novel
objects for 5 min. The time spent exploring each object
and the number of visits to each object was recorded
using an automated system (Viewer III Version 3.0.1.205,
Biobserve, St. Augustin, Germany).
An elevated Barnes maze apparatus (TSE Systems
GmbH, Bad Homburg, Germany; diameter 920 mm)
containing 19 empty holes and one hole with a hidden
escape chamber was used for testing spatial learning and
memory. Animals were trained for the Barnes maze task
for 4 days prior to testing. Each animal received 4 trials
per day, spaced at 15 min intervals for each of the 4 days
in order to learn the task. Extra-maze visual cues were
placed around the room and remained consistent
throughout the training and testing phase. During train-
ing, animals were allowed to freely explore for 3 min per
trial. Bright lights (75–85 lx) and a loud white noise
were used to motivate the animals to locate the escape
box. The number of errors (nose-pokes into incorrect
holes) and the latency to reach the target (hole with
escape box) was scored. To test short-term spatial mem-
ory retention, one 90-s trial was conducted on day 5
wherein the escape box was removed. The time to reach
the target hole (latency to target) and time spent in the
target zone was measured. To test long-term memory
retention, another 90-s trial was conducted 7 days later.
Behavior was recorded using an overhead camera and
automated software system (Viewer III Version 3.0.1.205,
Biobserve, St. Augustin, Germany).
Statistics
Statistical analyses were performed using the GraphPad
Prism 6 Software. Differences between two groups were
evaluated by Student’s t-test or Mann-Whitney test for
pairwise comparison of experimental groups or by one-
way ANOVA or two-way ANOVA with Bonferroni post-
tests for comparison of more than two experimental
groups, as indicated. Data are represented as means
+/− SEM. Statistical significance is indicated as follows:
* p < 0.05, ** p < 0.01 and *** p < 0.001.
Results
Expression of iP subunits is increased during aging and is
accelerated by Aβ-pathology in APPPS1 mice
Since previous data suggested an increase in iP gene
expression during aging and in plaque-associated glia cells
in APP/PS1 mice [41], we analyzed protein expression of
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LMP7 upon aging and in association with development of
Aβ-pathology in brains of APPPS1 mice that show a more
rapid Aβ-pathology than the APP/PS1 mice used in previ-
ous studies. While protein levels of LMP7 in brain ho-
mogenates were elevated during aging (from 49 to
250 days old mice, respectively) in wildtype littermate mice
(LMP7+/+: 49d vs. 250d; p = 0.0253; two-way ANOVA
followed by Bonferroni post-tests), this induction was sig-
nificantly enhanced by the presence of Aβ-pathology in
APPPS1 mice (LMP7+/+ vs. APPPS1;LMP7+/+: 49d ns;
120d p = 0.0222; 250d p = 0.0065; two-way ANOVA
followed by Bonferroni post-tests) (Fig. 1a–c). These
changes in protein expression were reflected in alterations
in total chymotryptic-like activity of the proteasome
(standard proteasomes and iPs) (Fig. 1d) that was found to
be significantly affected by Aβ-pathology in 250 days old
APPPS1 mice (LMP7+/+ vs. LMP7−/−: p = 0,0061 and
APPPS1;LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0001; two-
way ANOVA followed by Bonferroni post-tests) in which
plaque pathology was fully established. For the latter age
group, LMP7 deficiency resulted in significantly reduced
chymotryptic-like activity, which can be accounted by the
lack of functional iPs in the LMP7 deficient mice.
Aβ-related changes in iP subunit protein levels and func-
tion were paralleled by increased gene expression of the
PSMB8 (encoding for LMP7) (120d: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0020, and 250d: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0162; two-way ANOVA followed
by Bonferroni post-tests) and also another iP subunit gene
PSMB9 (encoding for LMP2) at 120 and 250 days of age,
respectively (Fig. 1e) (120d: LMP7+/+ vs. APPPS1;LMP7+/+:
p = 0.004 and 250d: LMP7+/+ vs. APPPS1;LMP7+/+:
p = 0.0014; two-way ANOVA followed by Bonferroni post-
tests). In contrast, there was no change in the expression
of PSMB10 (encoding for β2i/ Mecl-1).
To get a an insight in the regulation of iP subunit genes,
we examined the transcription of other interferon-
stimulated genes, namely of the IFN-stimulated gene 15
(isg15) and of the IFN-inducible protein 10 gene (cxcl10),
both acting as chemokines in the brain and serve as indi-
cators for type I IFN signaling. We found that their
expression was not significantly affected by aging (Fig. 1f),
while Aβ-pathology enhanced transcription of these genes
significantly at 120 days of age (isg15: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0165, and cxcl10: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0007; two-way ANOVA followed
by Bonferroni post-tests) indicating that increased iP
expression and function are associated with exacerbated
IFN-signaling in the brains of APPPS1 mice (Fig. 1f).
Indeed, analysis of gene expression levels of type I inter-
ferons, namely ifn-α and ifn-β revealed a transient upregu-
lation of their transcription at 120 days of age (ifn-β:
LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0410; two-way
ANOVA followed by Bonferroni post-tests) (Fig. 1g).
Thus, increased iP expression in APPPS1 mice is most
likely driven by type I IFN signaling.
IFN-signaling as well as AD have been shown to induce
oxidative damage to proteins. Since oxidatively damaged
proteins tagged by poly-ubiquitin conjugates are a target
for iPs [49], we analyzed the levels of poly-ubiquitinylated
proteins by Western blot. As expected, we observed a sig-
nificant increase of poly-ubiquitinylated proteins upon de-
velopment of Aβ-pathology in APPPS1;LMP7+/+ mice
compared to wild-type littermate control animals. How-
ever, the deficiency in iP subunits did not affect the levels
of poly-ubiquitinylated proteins in APPPS1;LMP7−/− mice
(Fig. 1h and i) suggesting an upregulation of standard
proteasome (sP) activity during the development of
Aβ-pathology. Since iPs are reported to be essential for
cell viability, the amount of oxidant damaged proteins
were analyzed indirectly by Western blot using an anti-
DNP antibody directed against ROS- changed carbonyl
groups of proteins. Indeed, iPs are essential for cell via-
bility as the amount of irreversibly damaged proteins is
significantly increased upon iP subunit deficiency in
LMP7−/− mice compared to LMP7+/+ littermate con-
trol mice (Fig. 1j and k). However, the concentration
of damaged proteins is not further changed during
Aβ-pathology.
LMP7 deficiency does not affect Aβ-pathology in APPPS1
mice
To test the potential impact of the observed increase in
iP expression levels on Aβ-plaque pathology in vivo, we
assessed the development and progression of Aβ-
pathology in presence or absence of iP activity in
APPPS1 mice harboring or lacking LMP7. Stereological
quantification revealed no difference in Aβ plaque
burden in brains of APPPS1 mice with or without func-
tional LMP7 during the onset of Aβ-pathology (120 days
of age; Fig. 2a and b; left panel), as well as in aged
APPPS1 mice exhibiting extensive Aβ-pathology (250 days
of age, Fig. 2a and b, right panel). In addition, the distribu-
tion of plaque sizes was similar in both experimental
groups (Fig. 2c and d). Biochemical analyses of total
Aβ-levels (Fig. 2e) as well as detailed analyses of soluble
and insoluble Aβ-species (Fig. 2f and g) corroborated
these findings. Moreover, expression of the amyloid
precursor protein (APP) and APP processing were
unaltered in APPPS1 mice lacking or harboring LMP7
(Fig. 3a–h). Furthermore, the amyloidogenic APP β-C
terminal fragment released from APP by BACE cleav-
age remained unchanged (Fig. 3i). These data demon-
strate that iP deficiency does not alter the development
of Aβ-pathology in APPPS1 mice, does not affect size
and solubility of Aβ-deposits and does not affect APP
processing.
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Fig. 1 (See legend on next page.)
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Microglia activity and pro-inflammatory cytokine levels
are reduced by iP deficiency in APPPS1 mice
Next we analyzed the effect of LMP7 deficiency on
inflammation in APPPS1 mice. Since iP activation upon
Aβ-pathology has been described mainly in glial cells,
we analyzed the effect of iP deficiency on microgliosis in
APPPS1 mice by stereologically analyzing microglia cells
(Fig. 4a and b). Despite there being no difference in Aβ
plaque burden, iP deficient APPPS1 mice displayed a
significant reduction in the number of and percentage of
area covered by Iba-1+ microglia cells compared to
APPPS1 mice with functional iPs (Fig. 4a and b, area cov-
ered: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0135;
unpaired t-test, two-tailed and number of Iba + microglia
cells: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0286;
unpaired t-test, two-tailed), indicating that iP deficiency
changes the microglial response to Aβ-pathology. The
slight reduction in the number of microglia in APPPS1
mice lacking LMP7 compared to those harboring
LMP7 was accompanied by changes in the concentra-
tion of pro-inflammatory secreted cytokines in vivo
(Fig. 4c and d), with a significant reduction of TNFα and
IL-6 levels (TNFα: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−:
p = 0.0079 and IL-6: APPPS1.LMP7+/+ vs. APPPS1;LMP7
−/−: p = 0.0079, Mann-Whitney test, two-tailed), while IL-
1β, IL-4 and IL-10 levels remained unchanged at 120 days
of age (Fig. 4c). However, this cytokine profile changed
upon aging and prolonged Aβ exposure. Aged (250 days
old) APPPS1 mice deficient in iPs still displayed a signifi-
cant reduction of TNFα in soluble brain extracts (TNFα:
APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0260; Mann-
Whitney test, two-tailed), while IL-6 levels were un-
changed. In contrast, the anti-inflammatory cytokines IL-4
and IL-10 levels were significantly increased in soluble
brain extracts of aged LMP7-deficient APPPS1 mice
(250 days old; Fig. 4d, (IL-4: APPPS1.LMP7+/+ vs.
APPPS1;LMP7−/−: p = 0.0223 and IL-10: APPPS1.LMP7+/+
vs. APPPS1;LMP7−/−: p = 0.0317; Mann-Whitney test,
two-tailed). The observed change in the microglia com-
partment was accompanied by an increase in astrogliosis
in iP deficient APPPS1 mice compared to iP competent
APPPS1 mice (Fig. 4e and f, area covered by GFAP+ astro-
cytes, APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: n = 5 mice
per group, *** p = 0.001, two-tailed Student’s t-test), most
likely secondary to the changes in microglia response and
cytokine secretion. Taken together, our results indicate a
role for iPs in modulating the glial response during the
course of Aβ-pathology in APPPS1 mice.
Microglia deficient in LMP7 subunits elicit attenuated
cytokine responses in vitro
Since we observed a modulation of microglia activity in
APPPS1 mice deficient in LMP7 in vivo, we examined
the effect of iP deficiency on microglia cytokine release
in vitro by culturing microglia isolated from mouse brain
tissues (Fig. 5a). As expected, primary microglia isolated
from 120 day old APPPS1 mice exhibited significantly
elevated levels of the pro-inflammatory cytokines TNFα
and IL-6 at baseline compared to wildtype littermate
control animals (Fig. 5b, TNFα: LMP7+/+ vs. APPPS1;LMP7
+/+: p = 0.0275; LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0394;
APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0252; IL-6:
LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0095; LMP7−/− vs.
APPPS1;LMP7+/+: p = 0.0307; APPPS1;LMP7−/− vs.
APPPS1;LMP7+/+: p = 0.0471; one-way ANOVA followed
by Bonferroni post-tests). While iP deficiency tended to
increase microglia cytokine release in the non-
pathological context, microglia isolated from APPPS1
mice deficient in iPs secreted significantly reduced
amounts of pro-inflammatory cytokines TNFα and IL-6
(See figure on previous page.)
Fig. 1 iP subunit expression in the brain is increased upon aging and enhanced in APPPS1 mice. a Western blot analysis of LMP7 expression in
brain homogenates of 49d, 120d and 250d old wildtype (LMP7+/+) and APPPS1;LMP7+/+ mice (respective littermate control LMP7−/− and
APPPS1;LMP7−/− mice served as a control for antibody specificity) and (b) corresponding densitometric quantification (right panel; n = 3–5 mice
per group, (LMP7+/+: 49d vs. 250d; p = 0.0253; LMP7+/+ vs. APPPS1;LMP7+/+: 49d ns; 120d p = 0.0222; 250d p = 0.0065; two-way ANOVA followed
by Bonferroni post-tests). c Native PAGE analysis of brain homogenates from LMP7+/+ and APPPS1;LMP7+/+ mice. Proteasome complexes were
visualized by western blotting for the iP subunit LMP7. d Total 26S chymotryptic peptide-hydrolyzing activity was analyzed in brain homogenates
from LMP7+/+, LMP7−/−, APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice using Suc-LLVY-AMC peptide hydrolysis (n = 5 per
group; LMP7+/+ vs. LMP7−/−: p = 0.0061; APPPS1;LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0001; two-way ANOVA followed by Bonferroni post-tests). e-g
Quantitative PCR analysis of PSMB8, PSMB9, PSMB10, isg15, cxcl10, Ifn-α and Ifn-β from whole brain tissue of LMP7+/+, LMP7−/−, APPPS1;LMP7+/+ and
respective littermate APPPS1;LMP7−/− mice (n = 5 per group; PSMB8 120d: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0020; 250d: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0162; PSMB9 120d: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0041; 250d: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0014; isg15 120d:
LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0165; cxcl10 120d: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0007; ifn-β: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0410;
two-way ANOVA followed by Bonferroni post-tests). h Western blot analysis of poly-ubiquitin conjugates in brain homogenates of 120 days
old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice as well as age-matched wild-type and LMP7−/− mice and (b) corresponding
densitometric quantification (n = 3–5 mice per group; *** p = 0.001, one-way ANOVA followed by Bonferroni post-tests). (j) Western blot analysis of
oxidant-damaged proteins in brain homogenates of 120 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice, as well as age-
matched wild-type and LMP7−/− mice using carbonyl-detection and (k) corresponding densitometric quantification (n = 2–4 mice per group; LMP7+/+
vs. LMP7−/−: p = 0.0096; LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0066; LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0023; ** p < 0.01, one-way ANOVA followed by
Bonferroni post-tests). (nd = not detected and na = not analyzed)
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Fig. 2 (See legend on next page.)
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(TNFα: APPPS1;LMP7−/− vs. APPPS1;LMP7+/+:
p = 0.0252 and IL-6: APPPS1;LMP7−/− vs. APPPS1;
LMP7+/+: p = 0.0471; one-way ANOVA followed by
Bonferroni post-tests), whereas levels of IL-1β and IL-10
were only slightly affected (Fig. 5b). The cytokine profiles
observed in isolated microglia in vitro corresponded to
the cytokine levels detected in whole brain homogenates
in vivo (Fig. 4c and d). After additional stimulation with
LPS to fully induce iP expression, secretion of all mea-
sured cytokines was significantly attenuated in APPPS1
mice lacking LMP7 compared to microglia isolated from
iP competent APPPS1 mice (Fig. 5c, TNFα: LMP7+/+ vs.
(See figure on previous page.)
Fig. 2 iP subunit deficiency has no impact on cerebral Aβ burden in young and aged APPPS1 mice. a Representative images of diffuse plaques
(4G8 antibody immunohistochemistry) and congophilic core plaques assessed by Congo Red staining in cortical sections of young and aged
APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (scale bar 100 μm) and (b) corresponding stereomorphological quantification
of Aβ plaque burden (n = 4–8 mice per group, p > 0.05, Mann-Whitney test). c Plaque size distribution analysis using the CellSense software in
the cerebral cortex of 120 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice and (d) aged 250 days old APPPS1;LMP7+/+
and respective littermate APPPS1;LMP7−/− mice (n = 3–5 mice per group, p > 0.05, two-way ANOVA, followed by Bonferroni post-tests). e Total
amounts of soluble and insoluble Aβ1–40 and Aβ1–42 species in brain homogenates of pre-plaque depositing, young 120 days old and aged250
days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice assessed by MSD 96-Well MULTI-SPOT® Human (6E10) Abeta Triplex
Assay (Meso Scale Discovery) (n = 4–8 mice per group, p > 0.05, one-way ANOVA followed by Bonferroni post-tests). f and (g) Amount of soluble
and insoluble Aβ1–40 and Aβ1–42 species calculated from individual protein fractions assessed by MSD 96-Well MULTI-SPOT® Human (6E10) Abeta
Triplex Assay (Meso Scale Discovery) in brain homogenates of (f) young 120 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/−
mice (n = 4–6 mice per group, p > 0.05, Mann-Whitney test) and (g) aged 250 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/−
mice (n = 5 mice per group, p > 0.05, Mann-Whitney test)
Fig. 3 iP subunit deficiency has no impact on APP processing, on cerebral Aβ production and sAPPβ levels in brain homogenates in APPPS1
mice. a and (e) Representative image of Western blot analysis of APP, APPCTFβ and Aβ in brain homogenates of young 120 days old (a; upper
panel) and aged 250 days old (e; lower panel) APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (6E10 detection) and corresponding
densitometric quantification (upper panel; b – d, and lower panel; f – h) (n = 4–6 mice per group, p > 0.05, Mann-Whitney test). i, Soluble APPbeta
levels in Tris fractions of 49 day old pre-depositing APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice assessed by Human Swedish
Soluble APPβ (sw sAPPβ) singleplex Meso Scale assay (Meso Scale Discovery) (n = 4 mice per group, p > 0.05, Mann-Whitney test)
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Fig. 4 (See legend on next page.)
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Fig. 4 iP subunit deficiency changes microgliosis and the inflammatory milieu in APPPS1 mice. a Representative images of Iba-1 immunohisto-
chemistry in cortical sections of 120 days old APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (left panels: scale bar 500 μm; right
panels: scale bar 100 μm). b Corresponding stereomorphological quantification of the Iba-1 area covered and numbers of Iba-1+ cells at 120 days
of age (n = 4–5 mice per group, area covered: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0135; number of Iba + microglia cells: APPPS1.LMP7+/+
vs. APPPS1;LMP7−/−: p = 0.0286; unpaired t-test, two-tailed). c Analysis of whole brain cytokine levels assessed by Meso Scale V-PLEX Plus Pro-
inflammatory Panel 1 (mouse) kit in brain homogenates of 120 days of age APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice
(n = 4–5 mice per group, TNFα: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0079; IL-6: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0079, Mann-
Whitney test). d Analysis of whole brain cytokine levels assessed by Meso Scale V-PLEX Plus Pro-inflammatory Panel 1 (mouse) kit in soluble brain
homogenates of 250 days of age APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (n = 4–5 mice per group, TNFα: APPPS1.LMP7
+/+ vs. APPPS1;LMP7−/−: p = 0.0260; IL-4: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0223; IL-10: APPPS1.LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0317,
Mann-Whitney test). e Representative images of GFAP–positive astrocytes detected by immunohistochemistry in cerebal cortical sections.
f Stereomorphological quantification of the GFAP area covered in APPPS1.LMP7+/+ and respective littermate APPPS1;LMP7−/− mice (n = 5 mice
per group, *** p = 0.001, two-tailed Student’s t-test)
Fig. 5 iP subunit deficiency alters cytokine secretion profile in adult microglia in vitro. a Schematic representation of experimental procedure for
microglia isolation, LPS stimulation and cytokine analyses. b Cytokine levels in supernatant of cultured enriched microglia form 120d old mice at
baseline assessed by Meso Scale V-PLEX Plus Pro-inflammatory Panel 1 (mouse) kit (Meso Scale Discovery) (n = 3–4 wells per group, TNFα: LMP7
+/+ vs. APPPS1;LMP7+/+: p = 0.0275; LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0394; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0252; IL-6: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0095; LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0307; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0471; one-way ANOVA followed
by Bonferroni post-tests). c Cytokine levels in supernatant of cultured enriched microglia isolated from 120d old mice after 14 h LPS stimulation
assessed by Meso Scale V-PLEX Plus Pro-inflammatory Panel 1 (mouse) kit (Meso Scale Discovery) (n = 3–4 wells per group, TNFα: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0002; LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0002; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.003; IL-6: LMP7+/+ vs. APPPS1;LMP7
+/+: p = 0.0002; LMP7−/− vs. APPPS1;LMP7+/+: p < 0.0001; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p < 0.0001; IL-1β: LMP7+/+ vs. APPPS1;LMP7+/+:
p < 0.0001; LMP7−/− vs. APPPS1;LMP7+/+: p < 0.0001; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0001; IL-10: LMP7+/+ vs. APPPS1;LMP7+/+: p < 0.0001;
LMP7−/− vs. APPPS1;LMP7+/+: p < 0.0001; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0002; one-way ANOVA followed by Bonferroni post-tests)
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APPPS1;LMP7+/+: p = 0.0002; LMP7−/− vs. APPPS1;LMP7
+/+: p = 0.0002; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+:
p = 0.003; IL-6: LMP7+/+ vs. APPPS1;LMP7+/+:
p = 0.0002; LMP7−/− vs. APPPS1;LMP7+/+: p < 0.0001;
APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p < 0.0001; IL-1β:
LMP7+/+ vs. APPPS1;LMP7+/+: p < 0.0001; LMP7−/− vs.
APPPS1;LMP7+/+: p < 0.0001; APPPS1;LMP7−/− vs.
APPPS1;LMP7+/+: p = 0.0001; IL-10: LMP7+/+ vs.
APPPS1;LMP7+/+: p < 0.0001; LMP7−/− vs. APPPS1;LMP7
+/+: p < 0.0001; APPPS1;LMP7−/− vs. APPPS1;LMP7+/+:
p = 0.0002; one-way ANOVA followed by Bonferroni
post-tests). These data demonstrate that the iP is involved
in modulating microglia cytokine secretion in the context
of Aβ-pathology and upon exogenous stimulation.
Cognitive deficts are attenuated by iP deficiency in
APPPS1 mice
To determine whether iP deficiency and its subse-
quent reduction in pro-inflammatory cytokines alters
cognitive function in AD model mice, we performed a
variety of behavioral tests with APPPS1 mice lacking
or harboring LMP7.
When examining performance in the novel object test,
a measure for cortical dependent memory function,
APPPS1 mice deficient in iP activity showed increased
exploration of and visits to the novel objects (Fig. 6a)
compared to APPPS1 mice with functional iP activity
(duration: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0475;
visits: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0209; one-
way ANOVA followed by Bonferroni post-tests), indicat-
ing improvement of cortical memory in iP deficient
APPPS1 mice. Analysis of spatial memory performance
in the Barnes maze test revealed normal learning and
memory abilities of wildtype and iP deficient mice.
APPPS1 mice with normal iP activity showed significant
impairment in learning the task (Fig. 6c, day 4: LMP7+/+
vs. APPPS1;LMP7+/+: p = 0.0033; LMP7+/+ vs. APPPS1;
LMP7−/−: p = 0.2096; two-way ANOVA followed by
Bonferroni post-tests), while APPPS1 mice deficient in
iPs showed a slight amelioration of these learning defi-
cits. This was demonstrated by a reduced latency to lo-
cate the escape chamber during the short-term memory
retention trial compared to cognitively-impaired APPPS1
mice with functional iP activity (Fig. 6d, short-term
retention: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0067 and
LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0322; long-term
retention: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0022;
APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0548;
LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0322; LMP7+/+ vs.
APPPS1;LMP7−/−: p = 0.0178; one-way ANOVA
followed by Bonferroni post-tests), indicating an mild
improvement of hippocampus-dependent memory im-
pairment by iP deficiency in APPPS1 mice.
Taken together, these data indicate a beneficial effect
of iP deficiency on cognitive performance in mice devel-
oping AD-like Aβ-pathology, which coincides with
reduced secretion of pro-inflammatory cytokines upon
modulation of iP function (Fig. 4a-e).
Discussion
We herein demonstrate that elements of the proteasome
system, namely iP subunits such as LMP7, are increased
in the CNS upon aging and that this phenomenon is fur-
ther accelerated by concomitant development of AD
associated Aβ-pathology in APPPS1 mice, most likely
mediated through type I interferon induction. Deletion
of functional iPs in APPPS1 mice modulates the Aβ-
associated inflammatory signature resulting in a mild
ameloriation of the pathology-associated behavioral pheno-
type, which is in line with the data of the Green lab [13, 51].
The proteasome system consisting of various isoforms
is a major defense mechanism against pathologic
changes in proteostasis and essential for cellular integ-
rity. Thus, it is expressed in all cells, including neurons,
microglia and astrocytes in the brain [31]. However, the
expression and activity of the various proteasome
isoforms varies between cell types. Induction of iP
expression was detected in cultured and IFNγ treated
microglia in vitro [52] as well as in plaque associated
microglia and astrocytes in vivo [41]. Whereas standard
proteasome (sP) activity is reduced in aging [26] and in
neurodegenerative disorders [27, 48] possibly leading to
protein aggregation, oxidation and neuronal degeneration,
the iP has been observed to be upregulated in human
brains in the context of ageing, AD and Huntington’s dis-
ease [16, 37]. However, the impact of in vivo iP inhib-
ition or deficiency on the development and progression
of neurodegenerative diseases such as AD has not been
studied to date.
Rodent studies have generated inconsistent data showing
decreased, unaltered and increased proteasomal capacity
during the course of aging [20, 57]. In the context of AD,
iP activity was shown to be impaired in a mouse model
exhibiting Aβ-pathology [2], despite increased expression
of iP subunits. In line with the latter finding, we also dem-
onstrate herein that expression levels of β5i/LMP7/PSMB8
iP subunits are increased upon aging, which are further
enhanced by concomitant deposition of Aβ in mice exhi-
biting AD-like pathology. This is also true for the expres-
sion of the β1i/LMP2/PSMB9 gene encoding another IP
subunit. Besides the changes in gene expression, we can
also show that the chymotryptic-like activity is increased
due to increased Aβ-pathology, which is in accordance
with a study by Orre and colleagues demonstrating that
proteasomal activity is upregulated in APP/PS1 mice [41].
It is very likely that the choice of animal models, of assays
used to measure iP activity, and the choice of time point
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of analysis account for some of the discrepancies regarding
changes in proteasome activity in previously published
studies. In our present study the induction of iP subunits
coincided with the transient upregulation of type I IFN
and other IFN-stimulated genes, which represents a likely
signaling pathway for the induction of iP subunit
expression. The induction of type I IFN-production and
the chemokine CXCL-10 was previously reported in cells
treated with proteasome inhibitors or in PRAAS patient’s
cells indicating that Aβ deposition impairs proteasome
function [8]. Furthermore, the axis of CXCL-10 and its re-
ceptor CXCR3 expressed on microglia have been
Fig. 6 Improved cognitive function of APPPS1 mice upon iP deficiency. a Aged APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice
underwent behavioral tests for cognition, LMP7+/+ and LMP7−/− mice served as controls. Percentage of time spent exploring the novel object
and percentage of visits to the new object in the Novel object recognition test (n = 8–10 mice per group; duration: LMP7+/+ vs. APPPS1;LMP7+/+:
p = 0.0475; visits: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0209; one-way ANOVA followed by Bonferroni post-tests). b Quantification of recorded track
lengths and respective mouse activity of APPPS1;LMP7+/+ and respective littermate APPPS1;LMP7−/− mice analyzed in the Open field arena
(n = 8–10 mice per group; p > p 0.05; one-way ANOVA followed by Bonferroni post-tests). c Latency to target and number of errors during training
trials during the Barnes maze paradigm (n = 8–10 mice per group; day 4: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0033; LMP7+/+ vs. APPPS1;LMP7−/−:
p = 0.2096; two-way ANOVA followed by Bonferroni post-tests). d Short-term and long-term memory retention trail: Quantification of latency to reach
the target and total time spent in the target zone during the Barnes maze paradigm (n = 8–10 mice per group; short-term retention: LMP7+/+ vs.
APPPS1;LMP7+/+: p = 0.0067; LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0322; long-term retention: LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0022;
APPPS1;LMP7−/− vs. APPPS1;LMP7+/+: p = 0.0548; LMP7+/+ vs. APPPS1;LMP7+/+: p = 0.0322; LMP7+/+ vs. APPPS1;LMP7−/−: p = 0.0178;
one-way ANOVA followed by Bonferroni post-tests)
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implicated in promoting plaque formation and behavioral
deficits in APPPS1 mice [30]. In addition, ablation of type
I IFN signaling has been shown to preserve cognitive func-
tion and cytokine pattern in a mouse model of AD [36].
The LMP7 deficient mouse model was initially used to
study the impact of iPs in antigen presention via MHC I
molecules. In addition, more recent studies demonstrat-
ing a pathogenetically relevant contribution of iPs in
inflammation-driven diseases [7, 17, 40, 49] not only
extended our knowledge on the role of iP, but provided
yet another rational to investigate their role in the
pathogenesis of AD, since inflammation-mediated pro-
cesses in AD are known to partake in disease progres-
sion. Deficiency of iP function did not substantially
impact Aβ plaque burden and soluble Aβ levels in
APPPS1 mice, although there was a trend to reduced
soluble Aβ levels at an early disease stage (120d). One
possible explanation is that iP-deficient mice may adapt
to their loss of iP activity by upregulation of sP activity.
Moreover, APPPS1 mice are known to overexpress toxic
Aβ species rapidly and at very high levels, thus eventu-
ally overriding rather small effects of iP deficiency on Aβ
plaque pathology.
Microglia are known to be key in promoting the patho-
genetically relevant contribution of the immune system in
AD by a vast release of inflammatory molecules. Secretion
of pro-inflammatory cytokines by microglia and associated
changes in phagocytic and neuroprotective properties are
a major contributing factor to the recently recognized
“cellular” phase of Alzheimer’s disease [14]. Upon deleting
iPs in APPPS1 mice we observed changes in cytokine
secretion of microglia which are likely due to an altered
control of regulatory factors of the nuclear factor-κ B
(NFκB) family that are important for cytokine release
[4, 6, 9, 39, 53]. In line with our observation in the
CNS, selective inhibition of β5i/LMP7 in activated
peripheral blood mononuclear cells (PBMCs) led to a
downregulation of cytokine production via the NFκB
pathway [39]. LPS-induced signaling pathways were
also significantly reduced in peritoneal macrophages
lacking immunoproteasome subunits [46] indicating
an important role for the iP in modulating the NFκB
signaling pathway and therefore cytokine release. Spe-
cifically, increased activity of iPs results in enhanced
degradation of NFκB inhibitor α (IkBα), which in turn
is more stable in the context of iP-deficiency [40, 49].
The observed changes in microglial activation and
cytokine secretion upon β5i/LMP7/PSMB8 deficiency
were accompanied by an increase in activated astrocytes.
Since microglial cytokines are known to modulate the
activation state of astrocytes [32, 50], these changes are
most likely secondary to the altered microglial cytokine
secretion profile, although we cannot exclude a direct
effect of β5i/LMP7/PSMB8 deficiency on astrocytes.
While CNS-derived soluble immune factors including
pro-inflammatory cytokines like IL-1β, TNFα and IL-6
have been studied intensely [10, 11, 21, 23, 29, 52, 55],
their role in AD is still a matter of debate, also due to
the fact that the respective results - at least for some of
the analyzed cytokines - is not always consistent [43].
Several studies altered cytokine levels through genetic
manipulation of pro- and anti-inflammatory molecules
with the aim of modulating chronic inflammation and
altering Aβ plaque burden in transgenic AD-like mice
[10, 11, 21, 23, 29, 55]. The diverse role of cytokines in
the progression of AD-like pathology is underscored by
recent observations showing that overexpression of the
anti-inflammatory cytokine IL-10 negatively affected
cognitive function [11], whereas IL-10 deficiency signifi-
cantly restored cognitive impairment of APPPS1 mice
[23]. In line with these later studies, we observed that
reduced pro-inflammatory cytokine levels upon iP defi-
ciency in APPPS1 mice were associated with improved
cognitive performance, although this recovery in cogni-
tion was not accompanied by detectable changes in Aβ
plaque pathology. Similarly, pharmacological elimination
of microglia resulting in amelioration of cognitive defi-
cits and reducing pro-inflammatory cytokines in AD-like
mice did not translate into changes in plaque burden
[13, 51]. Since the amount of amyloid plaque burden in
AD subjects does not necessarily correlate with the level
of functional deficits, this further supports the notion
that cognitive performance and the amount of amyloid
burden do not need to correlate inevitably [5, 47]. On
the other hand, studies in AD patients suggest that ele-
vated levels of pro-inflammatory cytokines are associated
with impaired cognitive function [10, 11, 21, 35, 55] and
highlight the potential of manipulation of this pro-
inflammatory response for improving cognitive function
without necessarily targeting Aβ deposition.
Conclusion
In conclusion, our data demonstrate that iP deficiency
is associated with reduced pro-inflammatory cytokine
secretion in vitro and in vivo independent of a major
impact on Aβ-pathology in a mouse model of AD.
The reduction of pro-inflammatory cytokine secretion
was accompanied by improvement of Aβ-pathology associ-
ated cognitive deficits, indicating that manipulation of
iP activity may be a novel strategy to manipulate
cytokine signaling and improve cognitive function in
AD independent of targeting Aβ deposition. Further-
more, the development of selective iP inhibitors [39]
may allow fine-tuned manipulation of cytokine signal-
ing pathways to make this a viable option for target-
ing the innate immune response in AD and other
neurodegenerative diseases.
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